z-logo
open-access-imgOpen Access
MeCP2 in central nervous system glial cells: current updates
Author(s) -
Kedarlal Sharma,
Juhi Singh,
Emma E. Frost,
Prakash P. Pillai
Publication year - 2018
Publication title -
acta neurobiologiae experimentalis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 55
eISSN - 1689-0035
pISSN - 0065-1400
DOI - 10.21307/ane-2018-007
Subject(s) - mecp2 , rett syndrome , microglia , neuroscience , epigenetics , neurodevelopmental disorder , astrocyte , central nervous system , biology , regulator , genetics , immunology , gene , inflammation , phenotype
avMethyl‑CpG binding protein 2 (MeCP2) is an epigenetic regulator, which preferentially binds to methylated CpG dinucleotides in DNA. MeCP2 mutations have been linked to Rett syndrome, a neurodevelopmental disorder characterized by severe intellectual disability in females. Earlier studies indicated that loss of MeCP2 function in neuronal cells was the sole cause of Rett syndrome. Subsequent studies have linked MeCP2 expression in CNS glial cells to Rett syndrome pathogenesis. In this review, we have discussed the role of MeCP2 in glial subtypes, astrocytes, oligodendrocytes and microglia, and how loss of MeCP2 function in these cells has a profound influence on both glial and neuronal function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom